21.72
+0.6(+2.84%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
N/A
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Mr. Zeeshan Saeed | Founder, Chief Executive Officer, President & Executive Co-Chairman | 218,635 | 1970 |
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | Chief Executive Officer of Lucid & Director | 0 | 1971 |
| Dr. Ashwini Joshi | Director of Pharmaceutical Development | 89,397 | N/A |
| Mr. Nathan Coyle CPA | Controller | 93,965 | 1981 |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical & Scientific Affairs | 178,208 | N/A |
| Mr. Donal Carroll CPA | Chief Financial Officer | 218,635 | 1977 |
| Mr. Anthony John Durkacz | Founder & Executive Co-Chairman | 218,635 | 1976 |
| Mr. Jason D. Sawyer | Head of Finance & Mergers and Acquisitions | 0 | N/A |
| Ms. Maryann Adesso | Corporate Secretary | 0 | N/A |
| Randell Mack | President of FSD BioSciences | 0 | N/A |
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.